Neuron protection ameliorates neurodegenerative symptoms in mice Chen-Jei Hong1, Chien-Tsun Kuan1 1Institute of Biologics, Development Center for Biotechnology
Neurological disorders affect millions of people around the world and the economic impact is enormous. However, neurologic diseases, including brain tumors, epilepsy, Parkinson's disease, motor neuron disease and dementia, are still in unmet medical need therapy areas. Neurological disorders are usually linked to neuroinflammation and the associated cytotoxicity has been attributed mainly to microglia in CNS. Drugs that bind to inflammatory receptors, modulating phagocytosis and chemokine release of microglia, have potential benefits for attenuating disease progression. Additionally, neuroprotective approaches have been studied for decades and show benefit outcomes in some neurodegenerative diseases, including safinamide inhibiting monoamine oxidase B activity in PD, rilutek reducing glutamate induced toxicity in ALS and amantadine ameliorating NMDA receptor triggered excitotoxicity in AD. Using neurodegeneration mouse model, we designed multiple approaches and investigated these drugs in symptoms progression, as well as animal survival. By screening multiple targets, several leads showed benefits on mice symptoms and survival after treatment. These leads are capable of further developing and Investigational New Drug application.
Credits: None available.
You must be logged in and own this product in order to